Your browser doesn't support javascript.
loading
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation.
Kocis, Paul T; Liu, Guodong; Makenbaeva, Dinara; Trocio, Jeffrey; Velott, Diana; Trainer, JoAnn B; Abdulsattar, Younos; Molina, Marta I; Leslie, Douglas L.
Afiliação
  • Kocis PT; Anticoagulation Clinic, Penn State Health, Milton S. Hershey Medical Center, Hershey, PA USA.
  • Liu G; Public Health Sciences, Penn State University, College of Medicine, Hershey, PA USA.
  • Makenbaeva D; Bristol-Myers Squibb, Plainsboro, NJ USA.
  • Trocio J; Pfizer, New York, NY USA.
  • Velott D; Public Health Sciences, Penn State University, College of Medicine, Hershey, PA USA.
  • Trainer JB; Pfizer, New York, NY USA.
  • Abdulsattar Y; Pfizer, New York, NY USA.
  • Molina MI; Bristol-Myers Squibb, Plainsboro, NJ USA.
  • Leslie DL; Public Health Sciences, Penn State University, College of Medicine, Hershey, PA USA.
Drugs Real World Outcomes ; 3(2): 165-173, 2016 Jun.
Article em En | MEDLINE | ID: mdl-27398295
ABSTRACT

BACKGROUND:

Frequency of administration (once daily versus more than once daily) is believed to be an important consideration affecting drug choice.

OBJECTIVE:

The aim of this study was to describe the characteristics of patients with non-valvular atrial fibrillation (NVAF) and the extent to which they take chronic medications, other than anticoagulants, more frequently than once daily.

METHODS:

Using data from a large, national database of health insurance claims, patients with a diagnosis of NVAF between 1 July 2008 and 30 September 2011 were identified, along with their prescription medications, to determine the proportion of patients taking chronic medications more than once a day. Prescription medications, co-morbidities, and CHADS2 and CHA2DS2-VASc scores were evaluated. CHADS2 assesses the risk of stroke in NVAF patients with the following risk factors Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, and history of prior Stroke or transient ischemic attack. The CHA2DS2-VASc score adds the following risk factors to the CHADS2 score Age 65-74 years, Vascular Disease, and Sex Category (Female).

RESULTS:

Overall, 324,172 patients with NVAF with mean CHADS2 and CHA2DS2-VASc scores of 1.51 and 3.08, respectively, were included in the study. Of these patients, 299,716 (92.5 %) took chronic medications, with an average of 6.9 medications per patient, and 215,527 (66.5 % of all patients or 71.9 % of those taking chronic medications) took medications more than once per day.

CONCLUSION:

Use of chronic medications other than anticoagulants is common among patients with NVAF, and medications are typically taken multiple times per day. The average number of medications per patient and multiple therapeutic classes prescribed underscore the clinical complexity of NVAF patients. Hence, the choice of a once daily anticoagulant versus a more than once daily anticoagulant may be less relevant in a real world NVAF population in terms of a potential convenience benefit.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Drugs Real World Outcomes Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Drugs Real World Outcomes Ano de publicação: 2016 Tipo de documento: Article